Evidence mapPaperPMID 35699175Full record

Trial reportJournal of the American Heart Association2022

Sex-Specific Differences in Clinical Outcomes After Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial.

Mina Madan, J Dawn Abbott, Ryan Lennon, Derek Y F So, Andrea M MacDougall, Mary Ann McLaughlin, Vishakantha Murthy, Jacqueline Saw, Charanjit Rihal, Michael E Farkouh and 3 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06665919 (Randomized Controlled Trial for Evaluating CYP2C19 Allele Genotype-guided Clopidogrel Treatment Outcomes in Real-world Practice After the ePCI), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06665919 nacompletednot on this mapstarted 2023, after this paper: background citation

Randomized Controlled Trial for Evaluating CYP2C19 Allele Genotype-guided Clopidogrel Treatment Outcomes in Real-world Practice After the ePCI

TypeinterventionalSponsorVistamedi Ltd.Ran2023 to 2025Enrolled283ConditionsCoronary Artery Disease, Clopidogrel Resistance, Coronary Thrombosis, Adverse Cardiac EventsArmsCYP2C19 Genotype-Guided Clopidogrel Treatment, CYP2C19 Genotype Guided Antiplatelet Treatment Alternative to Clopidogrel, The Conventional Clopidogrel Treatment
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 2 countries.

Mina MadanSchulich Heart CentreSunnybrook Health Sciences CentreUniversity of Toronto Toronto Ontario Canada.ORCID 0000-0003-0285-6569
J Dawn AbbottDivision of Cardiology Lifespan Cardiovascular Institute Warren Alpert Medical School of Brown University Providence RI.ORCID 0000-0002-2560-0155
Ryan LennonDepartment of Quantitative Health Sciences Mayo Clinic Rochester MN.ORCID 0000-0002-8366-8422
Derek Y F SoUniversity of Ottawa Heart Institute Ottawa Ontario Canada.ORCID 0000-0002-3909-5698
Andrea M MacDougallThunder Bay Regional Health Sciences Centre Thunder Bay Ontario Canada.
Mary Ann McLaughlinIcahn School of Medicine at Mount Sinai New York NY.
Vishakantha MurthyDepartment of Cardiovascular Medicine Mayo Clinic Rochester MN.
Jacqueline SawVancouver General HospitalUniversity of British Columbia Vancouver British Columbia Canada.ORCID 0000-0002-7027-984X
Charanjit RihalDepartment of Cardiovascular Medicine Mayo Clinic Rochester MN.ORCID 0000-0003-2044-4664
Michael E FarkouhPeter Munk Cardiac CentreUniversity of Toronto Ontario Canada.
Naveen L PereiraDepartment of Cardiovascular Medicine Mayo Clinic Rochester MN.ORCID 0000-0003-3813-3469
Shaun G GoodmanSt. Michael's HospitalUniversity of Toronto Ontario Canada.ORCID 0000-0001-8068-2440
TAILOR‐PCI Investigators *
Mayo Clinic · USSunnybrook Health Science Centre · CAThunder Bay Regional Health Sciences Centre · CAUniversity of British Columbia · CABrown University · USIcahn School of Medicine at Mount Sinai · USMayo Clinic in Arizona · USMayo Clinic in Florida · USSt. Michael's Hospital · CAUniversity of Ottawa · CAUniversity of Toronto · CA

Funding

NHLBI NIH HHS U01 HL128606NHLBI NIH HHS U01 HL128626
6 · The paper itself

Abstract

Background TAILOR-PCI (Tailored Antiplatelet Initiation to Lessen Outcomes due to decreased Clopidogrel Response After Percutaneous Coronary Intervention) studied genotype-guided selection of antiplatelet therapy after percutaneous coronary intervention versus conventional therapy with clopidogrel. The presence of

Indexed as

Acute Coronary SyndromeClopidogrelPercutaneous Coronary InterventionSex FactorsCytochrome P-450 CYP2C19FemaleHemorrhageHumansMaleMyocardial InfarctionPlatelet Aggregation InhibitorsTreatment OutcomeClopidogrelCytochrome P-450 CYP2C19Platelet Aggregation Inhibitorsgenotypesex differencesTAILOR‐PCI

Identifiers

PMID35699175
PMCPMC9238632
OpenAlexW4282835150

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.